The reiteration of the 'Sector Perform' rating and maintenance of the $21 price target by RBC Capital suggests a neutral outlook on Fusion Pharmaceuticals. This indicates that the analyst believes the stock is fairly valued at its current level, neither undervalued nor overvalued, which is why the short-term impact on the stock price is likely neutral.